DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial CAMBRIDGE, Mass. - Apr 12, 2007 - Dyax Corp. announced today positive topline results from its Phase 3, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Advisory Committee voted (6 yes, 5 no, 2 abstentions) ...
BOSTON (MarketWatch) -- Shares of Dyax Corp. plunged Wednesday, retreating as much as 30% at one point as the company announced that a collaboration agreement for its lead drug candidate DX-88 has ...
In what the company called part of a "multistep commercialization strategy" for DX-88, Dyax Corp. licensed North American and European rights to the intravenous formulation of the compound for use in ...
Co announces it has reached a mutual agreement with Genzyme (GENZ) to terminate their joint venture for the development and commercialization of DX-88 for hereditary angioedema. The termination ...
SAN FRANCISCO (Marketwatch) -- Dyax shares fell 13% in after-hours trade late Thursday after the Cambridge, Mass.-based company said it has received guidance in a recent meeting with the Food and Drug ...
Immunotherapy-based cancer vaccines could permanently kill tumors by stimulating immune cells in multiple ways. At the 27th Annual Meeting of the American Society... The U.S. FDA issued a May 9 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today positive topline results from its second Phase 3, placebo-controlled trial, EDEMA4, for its lead product candidate DX-88 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback